Mary Chapman, features writer —

The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech and technology companies to the multiple myeloma field and to advance new treatments. The $50 million independent, self-sustaining fund is focused on accelerating the foundation’s mission to deliver precision…

In 2003, Don Wright received a daunting diagnosis of multiple myeloma. But not only has the 78-year-old survived, he has thrived. He’s since run 100 marathons, and is preparing for June’s National Senior Games. The founder of eRace Cancer, a social media campaign to educate patients about advances…

To raise awareness of multiple myeloma and efforts to cure it, the International Myeloma Foundation (IMF) is gearing up for the start of Myeloma Action Month (MAM) on March 1. Hoping to involve patients and their families and the myeloma community at large, this year’s activities will focus on…

The Multiple Myeloma Research Foundation (MMRF) is growing and adjusting its executive team, with a focus on improving multiple myeloma patient outcomes and advancing its precision medicine program. Steve Labkoff, MD, becomes the organization’s first chief data officer, while Michael Andreini is the new chief operating officer.

Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish a Center for Blood Cancers. The center is expected to house a new, state-of-the-art program for multiple myeloma, complementing its current blood malignancy programs.

Thanks to a £10 million donation (about $13,000,000), Imperial College London will establish a center for multiple myeloma research at the institution’s Hammersmith Hospital campus. The gift, from benefactors Hugh and Josseline Langmuir, will support blood cancer research at Imperial and advance research on more effective treatments for…

In a new agreement, Ayala Pharmaceuticals will work with Novartis on the development and commercialization of AL102, an investigational treatment for multiple myeloma. The option-to-license deal calls for Ayala to receive a $10 million equity investment from Novartis. Ayala, a clinical company that develops treatments for genetically…

The Multiple Myeloma Research Foundation (MMRF) is launching a platform clinical trial aimed at investigating treatments for high-risk multiple myeloma patients. Building on the nonprofit’s landmark study that identified unique disease subtypes, it is the first platform trial exclusively for multiple myeloma patients. Called MyDRUG, the trial…

During a strenuous but spectacular hike, a team including four patients is traversing Nepal’s Khumbu region, encountering some of the world’s tallest mountains, and experiencing Sherpa culture, all in the name of raising awareness of multiple myeloma, and funding research to defeat it. A collaboration between CURE Media Group…

In an effort to inform multiple myeloma patients and their loved ones about cutting-edge research and what it means for them, Patient Power and Emory Winship Cancer Institute partnered to host a town meeting Sept. 23 in Atlanta. The free event was at the Hyatt Midtown Atlanta,…